Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

282113

Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

APG-2575, an investigational Bcl-2 inhibitor being developed by Ascentage Pharma, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). This designation is granted to medications with the potential to substantially improve care for rare diseases, defined as those that affect fewer than 200,000 people in the U.S. The designation comes with certain incentives, including a tax credit for clinical trial expenses, fee waivers…

You must be logged in to read/download the full post.